When is the second peak of Medikinet (methylphenidate)?

From the Guidelines

The second peak of Medikinet is not explicitly mentioned in the provided study, however, based on the information about the pharmacokinetics of methylphenidate, it can be inferred that the second peak may occur around 6-8 hours after ingestion, but this is not supported by the study 1. The study discusses the time-response characteristics of standard stimulants and the need for long-duration drugs, but it does not provide specific information about the second peak of Medikinet.

• The study mentions that MPH-SR20 begins to act 90 minutes after ingestion and its plasma level peak is lower than for a comparable dose of MPH-IR, with the peak benefit occurring at 3 hours 1.
• It also notes that sustained release MPH may not be as immediately helpful to children with ADHD due to its delayed onset of action and gradually decreasing plasma concentration after its peak at 3 hours 1.
• However, the study does not provide information about a second peak, and the information about Medikinet's pharmacokinetics is not available in the study 1.
• Therefore, the information about the second peak of Medikinet should be based on other sources, and it is recommended to consult the prescribing information or other reliable sources for the most accurate information about the pharmacokinetics of Medikinet.

From the FDA Drug Label

The FDA drug label does not answer the question.

From the Research

Medikinet Retard Pharmacokinetics

• The study 2 compared the bioequivalence of Medikinet Retard and Equasym Retard, both containing 20 mg methylphenidate hydrochloride, in healthy volunteers.
• The results showed that Medikinet Retard had a similar pattern of absorption and elimination as Equasym Retard, but with a somewhat slimmer profile, where the first peak was less pronounced.
• The second peak of Medikinet Retard was also lower than that of Equasym Retard, with both the lower confidence limit and point estimate below 80%.
• However, the study 3 compared the pharmacokinetics of two modified-release formulations of methylphenidate, Ritalin LA and Concerta, in healthy adults.
• The results showed that Ritalin LA had a distinctly biphasic pharmacokinetic profile, with a second peak occurring at 5.6 hours after administration.
• Although the study does not specifically mention Medikinet Retard, it provides information on the pharmacokinetics of another modified-release formulation of methylphenidate.

Peak Plasma Concentrations

• The study 2 found that Medikinet Retard had a lower second peak compared to Equasym Retard, but does not provide information on the exact time of the second peak.
• The study 3 found that Ritalin LA had a second peak at 5.6 hours after administration, but this may not be directly applicable to Medikinet Retard.
• The study 4 mentions that Medikinet Retard has a pharmacokinetic profile with peak plasma levels, but does not provide information on the exact time of the second peak.

Conclusion on Second Peak Time

• Based on the available studies, there is limited information on the exact time of the second peak of Medikinet Retard.
• However, the study 2 suggests that Medikinet Retard has a similar pattern of absorption and elimination as Equasym Retard, with a second peak occurring at some point after administration.
• Further studies would be needed to determine the exact time of the second peak of Medikinet Retard.